PET Scans Show Up to 34% Drop in Brain Inflammation in MSA Trial
TLSA sits 19% above its 52-week low of $0.866.
Summary
The third MSA patient in Tiziana's Phase 2 trial of intranasal foralumab showed up to a 34% reduction in neuroinflammation on PET imaging, consistent with the first two patients. This builds on the 6-K filed earlier today and adds quantitative detail and market reaction—shares rose 6%. The consistency across patients strengthens the case for the drug's mechanism in a rare neurodegenerative disease with no approved therapies. Topline data from the separate Phase 2a MS trial is expected in late Q3 or early Q4 2026.
At the time of this announcement, TLSA was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $132.1M. The 52-week trading range was $0.87 to $2.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.